NX1 ASX · Health Care

Nexalis Therapeutics Ltd

Announcements, last 12 months: 51
Price sensitive, last 12 months: 15
Followed on InvestorPA: Low (Outside the 20% most-followed companies on InvestorPA)

Latest announcements

Released	Headline	Actions
6 Oct 2026, 12:40 PM	Change of Director's Interest Notice - Darryl Davies
6 Oct 2026, 12:03 PM	Final Director's Interest Notice - Sean Williams
6 Oct 2026, 12:02 PM	Initial Director's Interest Notice - Niv Dagan
2 Oct 2026, 10:01 AM	Chair Appointment/Resignation
1 Sep 2026, 3:46 PM	Removal of draft wording in the directors report HY accounts Price sensitive	AI summary
31 Aug 2026, 5:57 PM	Half Yearly Report and Accounts Price sensitive	AI summary
31 Jul 2026, 1:07 PM	Jun26 Appendix 4C Cash Flow Report Price sensitive	AI summary
31 Jul 2026, 1:06 PM	Jun26 Quarterly Activities Report Price sensitive	AI summary
30 Jul 2026, 11:02 AM	Change in substantial holding
14 Jul 2026, 3:13 PM	Change of Director's Interest Notice - Sean Williams

Sign in to see all NX1 announcements.

Guidance history

31 Aug 2026	Nexalis Therapeutics Ltd expects to continue seeking alternate funding to resume clinical trial programs.
6 Jul 2026	NX1.ASX received $490k in RDTI proceeds in 2025.
28 May 2026	Nexalis secures up to $53 million in funding capacity for its clinical programs.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow NX1 to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.